Darmiyan

Darmiyan's BrainSee Software Receives De Novo FDA Approval

Our Vision: Precision Brain Health Screening & Monitoring for All

using our novel medical AI + brain imaging software

Darmiyan is a Persian word that means in-between. Our technology focuses on the space in between brain cells. We grade the health of that space so that people begin to understand what’s happening in between normal health and neurodegenerative disease.

About us

We are a team of neuroscientists, data scientists, healthcare experts and patient advocates focused on improving the lives of millions of people around the world who suffer from brain diseases. We decode the mysterious world of the brain through high-standard, neuroscience-powered AI methods to measure and monitor changes that happen in our brain tissue architecture in response to our environment, food, activities, mindset, and medications. Such powerful tools to give insights into our individual brains are currently missing. Darmiyan team and technology strive to open a new window into the human brain. We intend to improve the entire brain health paradigm for patients, healthcare providers, pharmaceutical companies and others working to advance brain health and wellness.

Mission

Our mission is to leverage 40 years of cutting edge neuroscience research combined with advanced medical image processing and advanced ML/AI to address the biggest healthcare challenge of our time: detecting neurodegenerative disease at early stages when treatments matter. We aim to provide an a la carte menu of brain tests, starting with an Alzheimer’s test. All our tests and technologies are developed with standards of excellence including the 4 pillars: high accuracy, non-invasiveness, seamless integration, and high accessibility around the world.

Our first target is dementia. Our goal is to help prevent or postpone it through:

Early detection of Alzheimer’s disease
Monitoring patient-specific response to interventions
Using data to advance drug development for Alzheimer’s disease

Drawing on over four decades of pioneering brain research, Darmiyan’s patented core technology offers unprecedented precision in quantifying cellular-level changes within every voxel (3D pixel) of a brain MRI scan.

This groundbreaking advancement paves the way for a suite of brain tests and diagnostic tools that are both accurate and non-invasive. By unlocking new insights into the human brain, our technology is set to revolutionize the diagnostic and therapeutic landscapes, ultimately enhancing brain health for people everywhere.

News

More news

Darmiyan CEO was selected by Fortune 40 under 40

BrainSee was validated by third-party investigators

FDA breakthrough designation granted to BrainSee

Pharma giant Eisai led a $6M round in Darmiyan

Testimonials

“Darmiyan’s AI, machine learning algorithm using unique MRI microscopic pixel analysis with macroscopic input has generated a very sensitive and specific five year prognosis for patients presenting with amnestic MCI. This technology has high test retest reliability and can be applied to any clinical grade MRI which is a very useful clinical tool to assist doctors advising patients with early memory complaints. In addition the BrainSee degeneration maps clearly show focal areas of degeneration. I believe this will be a widely used technology to assist doctors and patients navigating the difficult terrain of MCI.”

“I am the PI of a longitudinal Brain Aging Study at HMRI for more than ten years. Our goal is to identify prodromal biomarkers and potential mechanisms of early dementia pathology of the Alzheimer type. Objective measures such as Darmiyan’s BrainSee that can predict cognitive decline are strongly needed to recognize and monitor potential therapies. I have interacted with Darmiyan for over two years, sharing some of the data from our Brain Aging study participants. I am excited by the potential for objective ways such as Darmiyan’s approach to predict cognitive decline, which can lead to better outcomes for patients and the healthcare system.”

“As a member of the research team that evaluated Darmiyan’s solution for predicting conversion of cognitive impairment to Alzheimer’s dementia, I was impressed by the potential of this breakthrough technology. All study investigators are optimistic that the solution will be successful providing a much needed predictor of disease progression. It may therefore fill a significant diagnostic gap highly valued by patients, clinicians, and clinical researchers.”